Quantcast
Last updated on April 20, 2014 at 14:04 EDT

Latest Chemotherapy regimens Stories

2012-11-16 08:23:38

PARIS and TARRYTOWN, N.Y., Nov. 16, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion and recommended the granting of marketing authorization for ZALTRAP(®) (ziv-aflibercept) Injection for Intravenous Infusion in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI)...

2012-06-27 14:19:38

Trial led by St. Jude Children's Research Hospital investigators succeeds in keeping cure rates high for young patients with favorable-risk Hodgkin lymphoma while reducing their chances of serious treatment side effects A multicenter trial showed that nearly half of young patients with early-stage Hodgkin lymphoma can be cured without undergoing either irradiation or intensive chemotherapy that would leave them at risk for second cancers, infertility, heart and other problems later. St....

2012-06-26 10:24:25

Trial led by St. Jude Children's Research Hospital investigators succeeds in keeping cure rates high for young patients with favorable-risk Hodgkin lymphoma while reducing their chances of serious treatment side effects MEMPHIS, Tenn., June 26, 2012 /PRNewswire-USNewswire/ -- A multicenter trial showed that nearly half of young patients with early-stage Hodgkin lymphoma can be cured without undergoing either irradiation or intensive chemotherapy that would leave them at risk for second...

2012-06-14 22:20:41

AMSTERDAM, June 15, 2012 /PRNewswire/ -- "Hodgkin lymphoma has become one of the most curable malignancies in adults," was stated by Dr Andreas Engert, Professor of Hematology at the University Hospital of Cologne in Germany. Results of the German Hodgkin Study Group (GHSG) HD 15 trial are presented at the 17th Congress of the European Hematology Association in Amsterdam. Using the multi-agent chemotherapy regimen BEACOPP the GHSG demonstrated significantly better tumor...

2012-05-22 10:24:29

AUSTIN, Texas, May 22, 2012 /PRNewswire/ -- Prodigy Generics, a division of Prodigy Health Supplier Corporation (PHS), has launched injectable irinotecan. Irinotecan is the generic equivalent of the branded drug Camptosar by Pfizer. Prodigy partnered with eVenus Pharmaceutical Laboratories to develop a portfolio of oncology products. Irinotecan is the first of several ANDAs being developed through the partnership that will add consistent supply and exceptional value to the U.S. injectable...

2011-12-22 07:37:35

High-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT), for previously untreated patients with advanced follicular lymphoma (FL) does not improve overall survival compared with conventional-dose chemotherapy alone, according to an online study published December 21 in the Journal of the National Cancer Institute. Follicular lymphoma is the most common sub-type of non-Hodgkin's lymphoma in North America, characterized by a long natural history, with multiple remissions...

2011-12-11 10:00:00

SAN DIEGO, Dec. 11, 2011 /PRNewswire/ -- Lymphoma and myeloma are both malignant diseases that arise from lymphocytes, a subset of blood cells, and commonly involve lymph nodes and the bone marrow. Although considerable progress has been made in the treatment of these diseases, they remain a significant challenge for patients and their hematologists. New research introducing unique treatment approaches and targets for lymphoma and myeloma will be presented today at the 53rd Annual...

2011-12-01 07:33:18

(Ivanhoe Newswire) — Younger lymphoma patients given a more intensive chemotherapy regimen combined with rituximab live much longer, and are more than twice as likely to remain in remission 4 years later, compared to patients given standard chemo. Over the past decade, combined treatment with the monoclonal antibody rituximab and a standard chemotherapy regimen CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) has substantially improved outcomes in lymphoma patients...

2011-11-15 07:27:00

THOUSAND OAKS, Calif., Nov. 15, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the European Commission (EC) has approved a variation to the marketing authorization for Vectibix® (panitumumab) to include indications for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC) in first-line in combination with FOLFOX and in second-line in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based...

2011-07-27 07:35:00

QUEBEC CITY, July 27, 2011 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced the completion of patient recruitment for the ongoing Phase 3 trial with perifosine in refractory advanced colorectal cancer. The trial, involving over 430 patients, is being conducted pursuant to a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA) and with Fast Track Designation. It is sponsored by Keryx Biopharmaceuticals, Inc.,...